Skip to Content

Mircera (epoetin beta-methoxy polyethylene glycol) Disease Interactions

There are 2 disease interactions with Mircera (epoetin beta-methoxy polyethylene glycol):

Major

Erythropoiesis-Stimulating Agents (Includes Mircera) ↔ Hypertension

Severe Potential Hazard, Moderate plausibility

Applies to: Hypertension

The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension. These agents may cause blood pressure to rise. Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents. Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment. Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing. It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.

References

  1. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989): 992-1000
  2. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990): 947-55
  3. Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988): 97-100
  4. "Product Information. Epogen (epoetin alfa)." Amgen, Thousand Oaks, CA.
  5. "Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc, Raritan, NJ.
  6. Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991): 84-6
  7. Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994): s36-43
View all 7 references
Major

Erythropoiesis-Stimulating Agents (Includes Mircera) ↔ Pure Red Cell Aplasia

Severe Potential Hazard, Moderate plausibility

Applies to: Pure Red Cell Aplasia

The use of erythropoiesis-stimulating agents is contraindicated in patients that develop pure red cell aplasia that begins after treatment with erythropoietin protein drugs.

Mircera (epoetin beta-methoxy polyethylene glycol) drug Interactions

There are 31 drug interactions with Mircera (epoetin beta-methoxy polyethylene glycol)

Mircera (epoetin beta-methoxy polyethylene glycol) alcohol/food Interactions

There is 1 alcohol/food interaction with Mircera (epoetin beta-methoxy polyethylene glycol)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide